| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2575854 | The American Journal of Geriatric Pharmacotherapy | 2010 | 43 Pages |
Abstract
Conclusions: TBZ is a complicated drug in terms of its mechanism of action and its activities against the 3 major monoamines in the CNS, making it difficult to predict its efficacy and tolerability in patients with hyperkinetic movement disorders. It is associated with numerous adverse effects and several important drug-drug interactions. Much work remains to be done to determine the therapeutic potential of TBZ in the treatment of hyperkinetic movement disorders.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
David R.P. PharmD,